Research programme: megakaryocyte progenitor cell therapeutics - Cellerant Therapeutics

Drug Profile

Research programme: megakaryocyte progenitor cell therapeutics - Cellerant Therapeutics

Alternative Names: CLT-009 - Cellerant Therapeutics

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cellerant Therapeutics
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Acute radiation syndrome
  • No development reported Thrombocytopenia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombocytopenia in USA (Parenteral)
  • 11 Sep 2014 Preclinical trials in Acute radiation syndrome in USA (Parenteral)
  • 10 Oct 2012 Cellerant Therapeutics receives a Small Business Innovation Research phase I and phase II option grant from the National Cancer Institute to develop CLT 009 for Thrombocytopenia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top